The findings arrive at a moment when irritable bowel syndrome has become one of the most common and frustrating diagnoses in gastroenterology. Classified among disorders of gut-brain interaction, IBS produces abdominal pain, bloating, and disturbed bowel habits in the absence of visible structural damage, and it resists most pharmacological treatments. That therapeutic vacuum has made acupuncture an increasingly popular option, and clinical trials have repeatedly reported that patients improve after a course of needling. But those trials also routinely show that patients receiving sham acupuncture improve nearly as much, raising a question that has shadowed complementary medicine research for decades: how much of the benefit is the needle, and how much is the mind?

To answer it, the researchers searched eight databases — PubMed, Embase, the Cochrane Library, Web of Science Core Collection, and four major Chinese databases including CNKI, Wanfang, VIP, and CBM — from their inception through July 4, 2026. They included only randomized controlled trials in which sham acupuncture served as a comparator in IBS patients, and they registered the protocol prospectively with PROSPERO under the identifier CRD420251035956. The primary outcome was the response rate, the proportion of patients who reported meaningful improvement, while secondary outcomes tracked changes in the IBS Symptom Severity Scale, the IBS Quality of Life scale, and abdominal pain intensity scores. Effect sizes were expressed as risk differences and pooled pre-to-post changes with 95 percent confidence intervals.

The headline numbers are striking. In patients who received sham acupuncture, the combined response rate was 0.38, meaning roughly 38 of every 100 patients treated with a placebo procedure reported feeling meaningfully better. On the IBS Symptom Severity Scale, scores fell by a pooled 60.08 points, with a confidence interval running from 70.62 down to 49.54 points of improvement. Quality of life scores rose by 8.23 points on average, and abdominal pain intensity dropped by 1.39 points on standard rating scales. None of these changes came from needles that penetrated classical acupoints in the way traditional theory prescribes; they emerged entirely from procedures intended to mimic acupuncture without its specific effects.

What does a 60-point drop on the symptom severity scale actually mean in clinical terms? The IBS-SSS is a 500-point instrument that captures pain intensity, pain frequency, bloating, satisfaction with bowel habits, and overall interference with daily life, and clinicians generally regard shifts of 50 points or more as clinically meaningful. By that yardstick, the placebo response documented in this analysis is not a statistical curiosity but a genuine therapeutic effect — one large enough that patients experience it as relief. Similarly, the 1.39-point reduction in pain intensity, measured on visual analog or numerical rating scales, represents a noticeable easing of the cramping and discomfort that define the condition.

Perhaps the most consequential part of the study, however, is not the headline effect size but the heterogeneity hiding beneath it. When the researchers stratified trials by their methodological and diagnostic characteristics, clear patterns emerged. Studies that used the Rome IV diagnostic criteria — the current international standard for defining functional gastrointestinal disorders — tended to report lower placebo responses than those relying on older Rome III or earlier criteria. Trials judged to be at low risk of bias also yielded smaller placebo effects, as did studies that defined treatment response according to the stringent criteria recommended by the U.S. Food and Drug Administration for IBS clinical trials. In other words, the more rigorous and modern the trial, the smaller the apparent power of the sham needle.

That pattern carries a lesson that extends well beyond acupuncture. Placebo responses are not fixed properties of a treatment; they are shaped by how trials are designed, how patients are selected, how outcomes are defined, and how much room subjective judgment has to wander. Older diagnostic criteria that swept in more heterogeneous patient populations, and looser definitions of what counts as a response, both inflate the apparent benefit of an inert procedure. The FDA’s patient-reported outcome requirements, which demand sustained improvement in abdominal pain and stool pattern rather than a fleeting global impression, are specifically engineered to filter out noise — and the analysis suggests they do exactly that, compressing the placebo response toward more conservative estimates.

The mechanisms behind a placebo response of this magnitude are likely multiple and overlapping. Ritualized, hands-on treatment delivers a dense bundle of contextual cues: a practitioner’s attention, the sensory experience of needling, the expectation of relief, and repeated clinical contact over weeks. IBS is, by definition, a disorder of gut-brain interaction, in which visceral sensitivity, stress physiology, and central pain processing are tightly entangled — making it precisely the kind of condition in which expectation and conditioning can plausibly modulate symptoms through real neurophysiological pathways. The gut’s enteric nervous system, its bidirectional communication with the brain via the vagus nerve and hypothalamic-pituitary-adrenal axis, and the endogenous opioid and cannabinoid systems all provide biological conduits through which psychological context can translate into altered gut sensation and motility.

For acupuncture researchers, the implications cut in two directions. On one hand, the substantial placebo response documented here means that any future trial of real acupuncture in IBS must be powered and designed to detect benefits that exceed this baseline — a demanding threshold, given that the sham arm already delivers clinically meaningful improvement to more than a third of patients. On the other hand, the finding does not automatically invalidate acupuncture as a therapy; it reframes the question. If part of acupuncture’s effect in IBS is a potent, ritual-mediated placebo response, some researchers argue that harnessing that response deliberately and ethically could itself be a legitimate clinical strategy, particularly for a condition with few effective drugs. The authors of the analysis note that several factors — diagnostic criteria, risk of bias, and response definitions — can notably influence the size of the placebo component, and that understanding these moderators is essential for interpreting both past and future trials.

For patients and clinicians, the study is a reminder that improvement after treatment is real even when the mechanism is expectation rather than needle stimulation — and that honest science can quantify that effect without dismissing the suffering it relieves. The 977 patients in these twelve trials who felt better after sham acupuncture were not imagining their symptoms fading; their brains and guts were genuinely recalibrating in response to context, ritual, and care. Disentangling how much of acupuncture’s benefit in IBS comes from specific needling effects and how much from this powerful contextual machinery will require trials that meet the highest methodological standards — Rome IV criteria, low risk of bias, and FDA-grade outcome definitions — and the new analysis provides the benchmark against which those trials can now be judged. In the meantime, it stands as one of the clearest quantitative demonstrations that in the contested territory of mind-body medicine, the placebo needle is anything but inert.

Subject of Research: Placebo response to sham acupuncture in patients with irritable bowel syndrome

Article Title: Placebo response of sham acupuncture in patients with irritable bowel syndrome: a systematic review and meta-analysis

Article References: Xiang, P., Wang, X., Li, B., Li, H., Zheng, W., Fan, X., Jiao, J., Wang, Y., Li, J., & She, Y. (2026). Placebo response of sham acupuncture in patients with irritable bowel syndrome: a systematic review and meta-analysis. BMC Complementary Medicine and Therapies. https://doi.org/10.1186/s12906-026-05513-0

Image Credits: AI Generated

DOI: 10.1186/s12906-026-05513-0

Keywords: irritable bowel syndrome, sham acupuncture, placebo response, meta-analysis, systematic review, randomized controlled trials, IBS-SSS, gut-brain interaction, Rome IV criteria, abdominal pain, complementary medicine, clinical trial methodology

Electroacupuncture is a refinement of conventional acupuncture in which fine needles inserted at specific points on the body are connected to a device that delivers a controlled electrical current. The stimulation is thought to modulate nerve activity, enhance local blood flow, and trigger the release of endogenous signaling molecules, mechanisms that have made the technique a popular option for managing erectile dysfunction in China, where it is widely employed in clinical practice. Yet popularity is not proof. The authors of the protocol are candid about the problem: robust evidence supporting the efficacy of electroacupuncture specifically for erectile dysfunction after robotic prostatectomy remains scarce. Most existing studies are small, unblinded, or lack credible control procedures, leaving clinicians and patients alike without a trustworthy answer to a simple question: does it actually work?

The new trial is designed to answer that question with unusual methodological discipline. A total of 114 participants will be enrolled and randomized in a one-to-one ratio to receive either real electroacupuncture or a sham electroacupuncture procedure that mimics the sensory experience of treatment without delivering the same therapeutic stimulation. All participants, regardless of assignment, will undergo 24 treatment sessions spread over eight weeks, a schedule intended to deliver a meaningful cumulative dose of therapy while remaining practical for patients to complete. After the treatment phase ends, the researchers will follow every participant for an additional eight weeks to see whether any benefits persist, fade, or continue to accumulate once the needles are set aside.

The choice of a sham control is central to the trial’s credibility. Acupuncture trials are notoriously vulnerable to placebo effects, because patients inevitably know whether they are being needled. To blunt that bias, the researchers will use a sham procedure modeled on devices such as the Park Sham Placebo Acupuncture Device, a blunt, retractable needle that gives the sensation of penetration without actually piercing the skin in the same way, combined with electrical stimulation parameters designed to feel similar without engaging the same neural pathways. If patients in both arms report comparable sensations but only the real-treatment group improves on objective measures, the case for a genuine biological effect becomes far stronger than in trials that compare acupuncture against no treatment at all.

The primary outcome is the score on the International Index of Erectile Function, a five-item questionnaire widely regarded as the standard patient-reported measure of erectile function in clinical research. Known as the IIEF-5, the instrument asks men to rate aspects of their erectile ability, including confidence in achieving and maintaining erections and the satisfaction derived from intercourse. Changes in this score will serve as the trial’s headline result, but the investigators have cast a much wider net. Secondary outcomes include the Erectile Hardness Scale, which grades the rigidity of erections on a simple ordinal scale; questions two and three from the Sexual Encounter Profile, which capture whether an erection was achieved and whether it was hard enough for penetration during real-world encounters; and a visual analogue scale on which patients rate their own subjective sense of improvement.

What distinguishes this protocol from many acupuncture trials is its commitment to objective physiology. At baseline, week eight, and week sixteen, participants will provide serum samples for testosterone measurement, allowing the researchers to determine whether electroacupuncture influences the hormonal axis that underpins male sexual function. At the same time points, they will undergo assessments of penile hemodynamic parameters, the measurements of blood flow and vascular response that reveal whether the physical machinery of erection is actually recovering. Because erection is fundamentally a vascular and neurological event, these physiological endpoints could expose mechanisms that questionnaires alone cannot. If testosterone levels and penile blood flow shift in parallel with symptom scores, the trial will offer not just an efficacy verdict but a window into how the therapy might work.

The psychological dimension of post-surgical sexual recovery is also built into the design. Erectile dysfunction after prostate cancer surgery is rarely an isolated physical problem; it is entangled with anxiety, depression, and a diminished sense of masculinity that can strain relationships and delay help-seeking. The investigators will therefore administer the Hospital Anxiety and Depression Scale at baseline and at weeks four, eight, twelve, and sixteen, alongside the other questionnaire-based outcomes. Tracking mood over the same timeline as erectile function may reveal whether restoring sexual health lifts psychological well-being, or conversely whether treating anxiety is a prerequisite for physical recovery, questions that matter enormously for designing rehabilitation programs that treat the whole patient rather than a single symptom.

Statistical rigor receives equally careful attention. The protocol specifies that all analyses will adhere to the intention-to-treat principle, meaning that every randomized participant will be analyzed in the group to which they were assigned, regardless of whether they completed the full course of sessions. This approach preserves the balance achieved by randomization and guards against the inflated estimates that arise when only compliant patients are counted. The trial has been registered on the International Traditional Medicine Clinical Trial Registry under registration number ITMCTR2025001479, has received ethics approval from the Institutional Review Board of West China Hospital of Sichuan University under permission number 2024-1606, and will be conducted in accordance with the Declaration of Helsinki, with informed consent obtained from all participants. The work is funded by the National Key Research and Development Program of China and a Regional Innovation and Cooperation Project of the Science and Technology Department of Sichuan Province, with the funders playing no role in the study’s design, conduct, or reporting.

The stakes extend well beyond one clinic in Chengdu. Prostate cancer is among the most common cancers in men worldwide, and robotic-assisted radical prostatectomy has become a dominant surgical approach in high-income health systems, prized for its precision and faster recovery. Yet nerve-sparing techniques, however skillfully executed, do not guarantee preserved erectile function, and the pharmacological mainstays of treatment, the phosphodiesterase-5 inhibitors that many patients know by their brand names, do not work for everyone, particularly men whose nerve pathways were damaged during surgery. A validated non-pharmacological option would fill a genuine gap in post-surgical rehabilitation, offering an alternative for patients who cannot tolerate medication, who prefer to avoid it, or who simply do not respond to it. The authors note that if electroacupuncture proves effective, the findings would support its integration as a viable non-pharmacological option within post-surgical rehabilitation protocols.

For now, the appropriate stance is cautious anticipation. This publication is a study protocol, not a result; no patient has yet been treated and analyzed under its design, and the trial’s findings will only become meaningful once recruitment, treatment, and follow-up are complete. But the protocol itself is a signal of how complementary medicine research is maturing. By pairing a traditional technique with a sham-controlled design, objective vascular and hormonal endpoints, intention-to-treat analysis, and prospective trial registration, the West China Hospital team has built the kind of study that can genuinely move the field, whatever the outcome. If the results are positive, they could reshape rehabilitation after one of the most common cancer surgeries in the world. If they are negative, they will spare countless men an ineffective therapy and redirect research toward approaches more likely to help. Either way, the answer will be worth far more than the question cost.

Subject of Research: Electroacupuncture as a treatment for erectile dysfunction after robotic-assisted radical prostatectomy

Article Title: Electroacupuncture for erectile dysfunction in patients after robotic-assisted radical prostatectomy: study protocol for a randomized controlled trial

Article References: Li, J., Chen, Y., Yang, L., Wen, Q., Lv, J., Liu, Z., Liu, L., Li, N., Lu, L., & Dong, Q. (2026). Electroacupuncture for erectile dysfunction in patients after robotic-assisted radical prostatectomy: study protocol for a randomized controlled trial. BMC Complementary Medicine and Therapies. https://doi.org/10.1186/s12906-026-05616-8

Image Credits: AI Generated

DOI: 10.1186/s12906-026-05616-8

Keywords: electroacupuncture, erectile dysfunction, robotic-assisted radical prostatectomy, prostate cancer, randomized controlled trial, sham acupuncture, IIEF-5, testosterone, penile hemodynamics, acupuncture, urology, rehabilitation